These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15266257)

  • 1. K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
    Ruane PJ; Luber AD
    MedGenMed; 2004 Apr; 6(2):31. PubMed ID: 15266257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
    Sunpath H; Wu B; Gordon M; Hampton J; Johnson B; Moosa MY; Ordonez C; Kuritzkes DR; Marconi VC
    AIDS; 2012 Aug; 26(13):1679-84. PubMed ID: 22739389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and determinants of the K65R mutation in HIV-1 reverse transcriptase in tenofovir-naive patients.
    Winston A; Mandalia S; Pillay D; Gazzard B; Pozniak A
    AIDS; 2002 Oct; 16(15):2087-9. PubMed ID: 12370512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.
    Theys K; Snoeck J; Vercauteren J; Abecasis AB; Vandamme AM; Camacho RJ;
    J Antimicrob Chemother; 2013 Feb; 68(2):419-23. PubMed ID: 23027713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
    Grant PM; Taylor J; Nevins AB; Calvez V; Marcelin AG; Wirden M; Zolopa AR
    Antimicrob Agents Chemother; 2010 Apr; 54(4):1520-5. PubMed ID: 20124005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.
    Hoffmann CJ; Ledwaba J; Li JF; Johnston V; Hunt G; Fielding KL; Chaisson RE; Churchyard GJ; Grant AD; Johnson JA; Charalambous S; Morris L
    Antivir Ther; 2013; 18(7):915-20. PubMed ID: 23751421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
    Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
    Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
    Delaunay C; Brun-Vézinet F; Landman R; Collin G; Peytavin G; Trylesinski A; Flandre P; Miller M; Descamps D
    J Virol; 2005 Aug; 79(15):9572-8. PubMed ID: 16014919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
    Barnas D; Koontz D; Bazmi H; Bixby C; Jemsek J; Mellors JW
    Antivir Ther; 2010; 15(3):437-41. PubMed ID: 20516563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
    Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
    Kagan RM; Lee TS; Ross L; Lloyd RM; Lewinski MA; Potts SJ
    Antiviral Res; 2007 Sep; 75(3):210-8. PubMed ID: 17442410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.
    Svarovskaia ES; Margot NA; Bae AS; Waters JM; Goodman D; Zhong L; Borroto-Esoda K; Miller MD
    J Acquir Immune Defic Syndr; 2007 Oct; 46(2):174-80. PubMed ID: 17667333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
    Theys K; Vercauteren J; Snoeck J; Zazzi M; Camacho RJ; Torti C; Schülter E; Clotet B; Sönnerborg A; De Luca A; Grossman Z; Struck D; Vandamme AM; Abecasis AB
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1053-6. PubMed ID: 23183438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations.
    Valer L; Martín-Carbonero L; de Mendoza C; Corral A; Soriano V
    AIDS; 2004 Oct; 18(15):2094-6. PubMed ID: 15577635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Tenofovir DF in rescue regimens].
    López Bernaldo de Quirós JC
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():25-30. PubMed ID: 19195435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.
    Winston A; Pozniak A; Mandalia S; Gazzard B; Pillay D; Nelson M
    AIDS; 2004 Apr; 18(6):949-51. PubMed ID: 15060444
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.